AMR_Report_bf.pdf 8,22MB
1000 Titel
  • Novel policy options for reimbursement, pricing and procurement of AMR health technologies
1000 Titelzusatz weitere
  • final report
1000 Verantwortlich
  • authors: Sabine Vogler, Katharina Habimana, Stefan Fischer, Manuel Alexander Haasis ; project assistant: Monika Schintlmeister ; commissioned by the Global AMR R&D Hub ; Gesundheit Österreich Forschungs- und Planungs GmbH
1000 Beteiligung
Gesundheit Österreich GmbH (Herausgeber/in) |
1000 Autor/in
  1. Vogler, Sabine |
  2. Habimana, Katharina |
  3. Fischer, Stefan |
  4. Haasis, Manuel Alexander |
  5. Gesundheit Österreich GmbH |
1000 Katalog Id
  • HT020934113
1000 Erscheinungsort Wien
1000 Verlag Gesundheit Österreich Forschungs- und Planungs GmbH
1000 Erscheinungsjahr 2021
1000 Art der Datei
1000 Publikationstyp
  1. Monografie |
  2. Report |
1000 FRL-Sammlung
1000 Sprache der Publikation
1000 Abstract/Summary
  • Antimicrobial resistance (AMR) is a global health threat. A key pillar in the multi-faceted approach to tackle AMR includes the development and commercialisation of novel antibiotics to replace those to which patients are increasingly becoming resistant. Another approach is focused on diagnostics, which, among others, help decide whether or not the prescription of an antibiotic is required, thus reducing antibiotic consumption. Medicines and medical devices, hereinafter referred to as health technologies, usually enter the market of a country after the public authority has decided whether, and to what extent, the cost of the specific health technology will be paid for by the public payer. Linked to these reimbursement and procurement decisions, the price of the health technologies can also be determined by authorities. AMR health technologies have special characteristics such as a dearth of data and evidence, a value to society higher than added therapeutic benefit, and comparably low prices of antibiotics compared to diagnostics. These considerations are not yet well captured by the current standard policies on reimbursement, pricing and procurement. There is a need for a more finely tuned set of specific policy options. Against this backdrop, the study aimed to identify specific policy options in reimbursement, pricing and procurement that are able to incentivise production and market entry of AMR health technologies (novel antibiotics and diagnostics). Included are examples of national policies already in place for AMR health technologies as well as for health technologies with similar characteristics.
1000 Sacherschließung
ddc 610 Medizin und Gesundheit
1000 DOI 10.4126/FRL01-006427715 |
1000 Verlagsversion
1000 Dateien
1000 Umfang
  • 1 Online-Ressource (XVIII, 171 Seiten)
1000 Formschlagwörter
1000 Objektart monograph
1000 Beschrieben durch
1000 @id frl:6427715.rdf
1000 Erstellt am 2021-05-27T07:47:23.930+0200
1000 Erstellt von 25
1000 beschreibt frl:6427715
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Sun May 30 05:07:30 CEST 2021
1000 Objekt bearb. Thu May 27 07:48:48 CEST 2021
1000 ähnlich zu
1000 Vgl. frl:6427715
1000 Oai Id
  1. |
1000 Identisch zu
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Beschrieben durch
1000 Bestand
1000 Lobid

View source